Search

Your search keyword '"Ding, Zuochuan"' showing total 5 results
Start Over Author "Ding, Zuochuan"
5 results on '"Ding, Zuochuan"'

2. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury

Author

Miao, Yan, Ding, Zuochuan, Zou, Zhimiao, Yang, Yang, Yang, Min, Zhang, Xiaoqian, Li, Zeyang, Zhou, Liang, Zhang, Limin, Zhang, Xue, Du, Dunfeng, Jiang, Fengchao, and Zhou, Ping

Subjects
Original Article
Abstract

Cardiomyocytes, macrophages, and fibroblasts play important roles in inflammation and repair during myocardial ischemia/reperfusion injury (MIRI). Myeloid differentiation primary response 88 (MyD88) is upregulated in immunocytes, cardiomyocytes, and fibroblasts during MIRI. MyD88 induces the secretion of proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α), while fibroblasts are recruited and activated to mediate cardiac remodeling. The aim of this study was to assess the anti-MIRI effect and mode of action of the novel MyD88 inhibitor TJ-M2010-5. We synthesized TJ-M2010-5 and identified its target by co-immunoprecipitation, after which we established a murine MIRI model and tested the protective effect of TJ-M2010-5 by immunohistochemistry, flow cytometry, real-time PCR, and western blotting. Neonatal rat cardiomyocytes subjected to anoxia/reoxygenation were also isolated and their supernatants used to stimulate cardiac macrophagocytes and fibroblasts in vitro. MyD88 was found upregulated during the early and late phases after MIRI. The MyD88 inhibitor considerably improved cardiac function, reduced cardiomyocyte apoptosis, reduced IL-1β, IL-6, and TNF-α secretion, and inhibited CD80+CD86+MHCII+ macrophage and fibroblast migration. Moreover, TJ-M2010-5 markedly inhibited Toll-like receptor/MyD88 signaling in vivo and in vitro. Thus, our findings highlight TJ-M2010-5 as a potential therapeutic agent for MIRI treatment.

Published
2020

4. Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice

Author

Ding, Zuochuan, primary, Du, Dunfeng, additional, Yang, Yang, additional, Yang, Min, additional, Miao, Yan, additional, Zou, Zhimiao, additional, Zhang, Xiaoqian, additional, Li, Zeyang, additional, Zhang, Xue, additional, Zhang, Limin, additional, Wang, Xinqiang, additional, Zhao, Yuanyuan, additional, Jiang, Jipin, additional, Jiang, Fengchao, additional, and Zhou, Ping, additional

Published
2019
Full Text
View/download PDF

5. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury.

Author

Miao Y, Ding Z, Zou Z, Yang Y, Yang M, Zhang X, Li Z, Zhou L, Zhang L, Zhang X, Du D, Jiang F, and Zhou P

Abstract

Cardiomyocytes, macrophages, and fibroblasts play important roles in inflammation and repair during myocardial ischemia/reperfusion injury (MIRI). Myeloid differentiation primary response 88 (MyD88) is upregulated in immunocytes, cardiomyocytes, and fibroblasts during MIRI. MyD88 induces the secretion of proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α), while fibroblasts are recruited and activated to mediate cardiac remodeling. The aim of this study was to assess the anti-MIRI effect and mode of action of the novel MyD88 inhibitor TJ-M2010-5. We synthesized TJ-M2010-5 and identified its target by co-immunoprecipitation, after which we established a murine MIRI model and tested the protective effect of TJ-M2010-5 by immunohistochemistry, flow cytometry, real-time PCR, and western blotting. Neonatal rat cardiomyocytes subjected to anoxia/reoxygenation were also isolated and their supernatants used to stimulate cardiac macrophagocytes and fibroblasts in vitro . MyD88 was found upregulated during the early and late phases after MIRI. The MyD88 inhibitor considerably improved cardiac function, reduced cardiomyocyte apoptosis, reduced IL-1β, IL-6, and TNF-α secretion, and inhibited CD80+CD86+MHCII+ macrophage and fibroblast migration. Moreover, TJ-M2010-5 markedly inhibited Toll-like receptor/MyD88 signaling in vivo and in vitro . Thus, our findings highlight TJ-M2010-5 as a potential therapeutic agent for MIRI treatment., Competing Interests: None., (AJTR Copyright © 2020.)

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results